Chancery Lets Fresenius Ditch $4.3B Akorn Deal
Pharmaceutical company Fresenius Kabi AG can walk away from its proposed $4.3 billion acquisition of Akorn Inc., a Delaware Chancery judge determined Monday, saying regulatory compliance issues at Akorn triggered the...To view the full article, register now.
Already a subscriber? Click here to view full article